在CITIUS ONCOLOGY INC(简称CTOR)开展的I期临床研究中,其候选药物Lymphir展现出良好的安全性与耐受性。研究结果显示,在整个试验过程中,未观察到任何剂量限制性毒性事件,为后续临床开发奠定了坚实基础。这一积极数据进一步增强了该药物在肿瘤治疗领域的应用潜力。
在CITIUS ONCOLOGY INC(简称CTOR)开展的I期临床研究中,其候选药物Lymphir展现出良好的安全性与耐受性。研究结果显示,在整个试验过程中,未观察到任何剂量限制性毒性事件,为后续临床开发奠定了坚实基础。这一积极数据进一步增强了该药物在肿瘤治疗领域的应用潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.